CompletedPhase 1NCT01893775

Antibody Treatment for Advanced Celiac Disease

Studying Refractory celiac disease

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Thomas A Waldmann, M.D.
National Cancer Institute (NCI)
Intervention: Hu-Mik- Beta-1(biological)
Enrollment: 5 enrolled
Eligibility: 18-100 years · All sexes
Timeline: 2013 – 2019

Study locations (1)

Mayo Clinic, Rochester, Rochester, Minnesota, United States

Collaborators

Mayo Clinic

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01893775 on ClinicalTrials.gov

← Back to all trials